112 related articles for article (PubMed ID: 38070430)
21. Down-regulation of cathepsin S and matrix metalloproteinase-9 via Src, a non-receptor tyrosine kinase, suppresses triple-negative breast cancer growth and metastasis.
Gautam J; Banskota S; Lee H; Lee YJ; Jeon YH; Kim JA; Jeong BS
Exp Mol Med; 2018 Sep; 50(9):1-14. PubMed ID: 30185799
[TBL] [Abstract][Full Text] [Related]
22. Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth.
Ren C; Zhang G; Han F; Fu S; Cao Y; Zhang F; Zhang Q; Meslamani J; Xu Y; Ji D; Cao L; Zhou Q; Cheung KL; Sharma R; Babault N; Yi Z; Zhang W; Walsh MJ; Zeng L; Zhou MM
Proc Natl Acad Sci U S A; 2018 Jul; 115(31):7949-7954. PubMed ID: 30012592
[TBL] [Abstract][Full Text] [Related]
23. Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer.
Pascual-Reguant L; Serra-Camprubí Q; Datta D; Cianferoni D; Kourtis S; Gañez-Zapater A; Cannatá C; Espinar L; Querol J; García-López L; Musa-Afaneh S; Guirola M; Gkanogiannis A; Miró Canturri A; Guzman M; Rodríguez O; Herencia-Ropero A; Arribas J; Serra V; Serrano L; Tian TV; Peiró S; Sdelci S
EMBO Mol Med; 2023 Dec; 15(12):e18459. PubMed ID: 37937685
[TBL] [Abstract][Full Text] [Related]
24. BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways.
Zhang Y; Xu B; Shi J; Li J; Lu X; Xu L; Yang H; Hamad N; Wang C; Napier D; He S; Liu C; Liu Z; Qian H; Chen L; Wei X; Zheng X; Huang JA; Thibault O; Craven R; Wei D; Pan Y; Zhou BP; Wu Y; Yang XH
Cell Oncol (Dordr); 2020 Dec; 43(6):1049-1066. PubMed ID: 33006750
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Akt/mTOR pathway overcomes intrinsic resistance to dasatinib in triple-negative breast cancer.
Haga Y; Higashisaka K; Yang L; Sekine N; Lin Y; Tsujino H; Nagano K; Tsutsumi Y
Biochem Biophys Res Commun; 2020 Dec; 533(4):672-678. PubMed ID: 33036754
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
[TBL] [Abstract][Full Text] [Related]
27. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.
Sun H; Zhang D; Yao Z; Lin X; Liu J; Gu Q; Dong X; Liu F; Wang Y; Yao N; Cheng S; Li L; Sun S
Cancer Biol Ther; 2017 Apr; 18(4):205-213. PubMed ID: 28278077
[TBL] [Abstract][Full Text] [Related]
28. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
29. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
[TBL] [Abstract][Full Text] [Related]
30. Combination Nano-Delivery Systems Remodel the Immunosuppressive Tumor Microenvironment for Metastatic Triple-Negative Breast Cancer Therapy.
Bai L; Liu H; You R; Jiang X; Zhang T; Li Y; Shan T; Qian Z; Wang Y; Liu Y; Li C
Mol Pharm; 2024 May; 21(5):2148-2162. PubMed ID: 38536949
[TBL] [Abstract][Full Text] [Related]
31. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
32. A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune.
Jiang Z; Cai G; Liu H; Liu L; Huang R; Nie X; Gui R; Li J; Ma J; Cao K; Luo Y
J Nanobiotechnology; 2024 May; 22(1):296. PubMed ID: 38811964
[TBL] [Abstract][Full Text] [Related]
33. Identification of a Triple Drug Combination That Is Synergistically Cytotoxic for Triple-Negative Breast Cancer Cells Using a Novel Combination Discovery Approach.
Ahmad S; He Q; Williams KP; Scott JE
SLAS Discov; 2020 Sep; 25(8):923-938. PubMed ID: 32441190
[TBL] [Abstract][Full Text] [Related]
34. Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.
Sahni JM; Gayle SS; Bonk KL; Vite LC; Yori JL; Webb B; Ramos EK; Seachrist DD; Landis MD; Chang JC; Bradner JE; Keri RA
J Biol Chem; 2016 Nov; 291(45):23756-23768. PubMed ID: 27650498
[TBL] [Abstract][Full Text] [Related]
35. Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells.
Tian J; Raffa FA; Dai M; Moamer A; Khadang B; Hachim IY; Bakdounes K; Ali S; Jean-Claude B; Lebrun JJ
Br J Cancer; 2018 Dec; 119(12):1495-1507. PubMed ID: 30482914
[TBL] [Abstract][Full Text] [Related]
36. Dasatinib prevents skeletal metastasis of osteotropic MDA-MB-231 cells in a xenograft mouse model.
Heilmann T; Rumpf AL; Roscher M; Tietgen M; Will O; Gerle M; Damm T; Borzikowsky C; Maass N; Glüer CC; Tiwari S; Trauzold A; Schem C
Arch Gynecol Obstet; 2020 Jun; 301(6):1493-1502. PubMed ID: 32170411
[TBL] [Abstract][Full Text] [Related]
37. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
[TBL] [Abstract][Full Text] [Related]
38.
Wan X; Sun R; Bao Y; Zhang C; Wu Y; Gong Y
Mol Pharm; 2021 Nov; 18(11):3990-3998. PubMed ID: 34591491
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases.
Shin SU; Cho HM; Das R; Gil-Henn H; Ramakrishnan S; Al Bayati A; Carroll SF; Zhang Y; Sankar AP; Elledge C; Pimentel A; Blonska M; Rosenblatt JD
Cells; 2021 Oct; 10(11):. PubMed ID: 34831127
[TBL] [Abstract][Full Text] [Related]
40. COL8A1 facilitates the growth of triple-negative breast cancer via FAK/Src activation.
Sato F; Sagara A; Tajima K; Miura S; Inaba K; Ando Y; Oku T; Murakami T; Kato Y; Yumoto T
Breast Cancer Res Treat; 2022 Jul; 194(2):243-256. PubMed ID: 35624176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
